Glucose‐lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification
Authors' conclusion
Individuals with CKD and T2D had many combinations of therapies and substantial follow-up time on therapy. These results highlight opportunities for improved CKD management.
Study context
- Population
- Adults ≥18 years with chronic kidney disease (CKD) (two consecutive estimated glomerular filtration rate (eGFR) 15-<75 mL/min/1.73 m², 90–730 days apart) and T2Dtwo databases
- Participants
- 36,951 vs 4,339
- Exposure
- Clinical Practice Research Datalink (CPRD) vs LCED
- CPRDn = 36,951
- LCEDn = 4,339
- Outcome
- Chronological treatment pathways for glucose-lowering therapies from CKD index; median time and proportion of follow-up on each therapy
- Follow-up
- CKD index to end
Methodological detailsdescriptive treatment-pathway analysis, two databases (UK CPRD-HES; US LCED)
- Descriptive treatment-pathway analysis
- Two databases (UK CPRD-HES; US LCED)
Main finding
As reported in the abstract
Time on metformin during follow-up
- Share of follow-up time on metformin, both databases
- ≈75%
Observational data: associations, not effects.
Further findings
Baseline characteristics · median baseline
- Median baseline eGFR, CPRD vs LCED (mL/min/1.73 m²)
- 67.8 vs 64.9
- Received metformin prior to index, CPRD vs LCED
- 64.2 vs 63.9%
Original publication
Glucose‐lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med. Published 26 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →